Eloralintide is an experimental once-a-week injection from Eli Lilly that copies amylin, a hormone your pancreas releases alongside insulin that slows the stomach and helps tell your brain a meal is over. It is not approved anywhere, and nobody can be prescribed it outside a clinical trial. It's in the news because on September 15, 2026, Lilly said that adding eloralintide to a low dose of tirzepatide led to about 17% weight loss over 16 weeks, against about 10% on tirzepatide alone.
That's a real signal, and an early one: a short, early-stage study, announced in a press release rather than a published paper, and measured against one of tirzepatide's lower doses.
What Lilly announced about eloralintide
The announcement previewed Lilly's data for the European Association for the Study of Diabetes (EASD) meeting in Milan, September 28 to October 2, 2026. In its September 15 release, the company said a phase 1 study (the first, smallest stage of testing in people, mainly about safety) found that eloralintide 3 mg added to tirzepatide 5 mg led to 17% weight loss over 16 weeks, versus 10% with tirzepatide 5 mg alone, in adults with obesity or overweight.
Lilly calls the pairing eloraTZP. Two details matter:
- The figures use the "efficacy estimand": the result as if everyone had kept taking the drug as assigned, which usually reads a little better than counting everyone who started.
- The release gives no group sizes and no side-effect figures for that study.
A larger phase 2 study of the pair, in adults with obesity or overweight and type 2 diabetes, is due to be presented on September 30; its registry record (NCT06603571) lists 367 people followed for 48 weeks.
As of September 22, 2026, the day this article was written, neither result had been presented, and no study of eloralintide combined with tirzepatide in people had appeared in a medical journal.
Why pair amylin with tirzepatide
Your body has several ways of saying "that's enough". Tirzepatide imitates two, the gut hormones GLP-1 and GIP. Amylin is another. It comes from the same pancreatic cells as insulin, slows how fast the stomach empties, holds back glucagon (the hormone that pushes blood sugar up), and acts in the brain to end a meal, as a 2026 review in Diabetes, Obesity and Metabolism lays out.
Because the signals travel different routes, the hope is that they add up. In a Lilly poster at the American Diabetes Association meeting in June 2026, obese rats given both drugs for four weeks lost about 20% of their weight, against about 10% on either drug alone. Rats are a starting point, not a forecast.
Eloralintide was also built to be choosier. In lab tests it favored its main amylin receptor about twelvefold over the related calcitonin receptor, and in rats it caused less taste aversion (a stand-in for nausea) than Novo Nordisk's amylin drug, cagrilintide (Briere et al., Molecular Metabolism 2025). Whether that means fewer stomach problems in people is still being tested.
What the eloralintide news means if you take tirzepatide
For now, nothing changes about what can be prescribed. Eloralintide is investigational and given only to trial participants; tirzepatide is the half of eloraTZP a provider can consider today.
Read the comparison slowly. The pair was measured against tirzepatide 5 mg, the lowest of the three doses tested in the large SURMOUNT-1 trial. And 16 weeks is early: in SURMOUNT-1, a 72-week study of 2,539 adults, people assigned 5 mg had lost 15.0% of their weight on average by the end, against 3.1% on placebo (Jastreboff et al., New England Journal of Medicine 2022). Whether the 16-week gap holds over a year, and how the pair compares with tirzepatide at 10 or 15 mg, are open questions.
What the result does add is an early sign that amylin's signal adds to tirzepatide's in people, not only in rats. Lilly's longer trials exist to test exactly that.
What eloralintide did on its own
The fullest data so far are for eloralintide alone. A phase 2 trial published in The Lancet in late 2025 enrolled 263 U.S. adults with obesity, or overweight plus a weight-related condition, and no type 2 diabetes. Over 48 weeks, average weight loss ran from about 9% on the lowest dose (1 mg) to about 20% on the highest (9 mg), against 0.4% on placebo, again counted as if everyone stayed on treatment.
Nausea and fatigue were the most common side effects, and both varied with the dose and how it was reached:
| Phase 2 group | Nausea | Fatigue |
|---|---|---|
| Placebo | 14% | 12% |
| 6 mg | 64% | 29% |
| 9 mg | 33% | 43% |
| 6 mg rising to 9 mg | 54% | 46% |
| 3 mg rising to 9 mg | 25% | 21% |
Fatigue stands out against placebo, and the group that started at 3 mg and stepped up reported far less nausea than the 6 mg group.
An earlier 12-week phase 1 study of 100 people reported 2.6% to 11.3% average weight loss across doses, with nausea in 8% of those on eloralintide (Bhattachar et al., Diabetes, Obesity and Metabolism 2026).
What it does not mean
It is not a published trial. A press release leads with the numbers a company chooses; group sizes, dropouts and side effects come later.
It is not a forecast. Seventeen percent at 16 weeks says nothing firm about a year.
It is not a win over full-dose tirzepatide. Nobody has reported that comparison.
It is not a reason to shop online. Vials sold under the eloralintide name without a prescription, often labeled for laboratory use, are not the trial drug: no prescriber, no pharmacy of record, nobody to call if the contents are wrong. Adding one to a prescribed GLP-1 medicine means stacking an unknown injectable on a drug that already slows the stomach.
What to watch next
- September 30, 2026: the phase 2 eloraTZP results in type 2 diabetes, at EASD. The side-effect table and how many people stopped matter as much as the weight figure.
- The ENLIGHTEN phase 3 trials, the large studies regulators rely on, which Lilly began in December 2025. ENLIGHTEN-1 compares eloralintide with placebo in about 1,980 adults without type 2 diabetes over 64 weeks, with main measurements due to finish around March 2028 (NCT07321886). ENLIGHTEN-6 is closest to home: it adds eloralintide or placebo for people still living with obesity on a weekly incretin (the drug family that includes tirzepatide and semaglutide), due around June 2028 (NCT07392190).
- The rival pairing. Novo Nordisk's CagriSema combines cagrilintide with semaglutide; its results against tirzepatide are in CagriSema vs tirzepatide. Lilly's other late-stage candidate is covered in tirzepatide vs retatrutide.
Semaglutide, the GLP-1 half of CagriSema, is also something a provider can weigh on its own today.
What a provider can weigh today
The newest molecule is almost always the one nobody can prescribe yet. What a provider can weigh with you now is what exists: tirzepatide or semaglutide, set against your medical history, your other medicines, and how you've handled similar drugs before.
Through Promise, tirzepatide and semaglutide are dispensed as compounded medications, which are different from an FDA-approved product: the formulations offered here are not FDA-approved. Compounded tirzepatide explains what that preparation is and is not. A licensed provider may still prescribe a compounded formulation where they judge it appropriate, and that decision is between you and your doctor.
At Promise, a licensed provider reviews every request and prescribes only when a medication is appropriate for you. Not everyone qualifies.